コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 rization with activity comparable to that of combretastatin A-1 (3a), the phosphorylated derivative (
3 t, the corresponding carbonate derivative of combretastatin A-4 (13) was unstable in aqueous environm
4 eries of cis- and trans-stilbenes related to combretastatin A-4 (1a), with a variety of substituents
5 ombretum caffrum) antineoplastic constituent combretastatin A-4 (1b) directed at maintaining the (Z)-
8 sent SAR studies of the antineoplastic agent combretastatin A-4 (1c) were focused mainly on the olefi
9 served with the phosphorylated derivative of combretastatin A-4 (1d), phosphate 3d retained detectabl
10 ombretum caffrum) antineoplastic constituent combretastatin A-4 (3b) led to the discovery of a potent
11 phenolic anticancer drugs etoposide (6) and combretastatin A-4 (7) were attached to the Z-val-cit-p-
12 y-1H-indoles were obtained as a new class of combretastatin A-4 (CA-4) analogues via a convenient ult
13 eric derivatives designed as cis-constrained combretastatin A-4 (CA-4) analogues were synthesized and
21 vel 2,5-diaryl-1,3,4-oxadiazoline analogs of combretastatin A-4 (CA-4, 1) were designed, synthesized,
24 zole scaffold and designed as cis-restricted combretastatin A-4 analogues, was synthesized with the g
25 nt inhibition of tubulin polymerization than combretastatin A-4 and strong binding to the colchicine
26 mitotic natural products podophyllotoxin and combretastatin A-4 and to that of NSC 664171, a particul
27 embranes, which was similar to cisplatin and combretastatin A-4 and without significant toxicity towa
28 Compounds 9i and j were more active than combretastatin A-4 as inhibitors of tubulin polymerizati
32 The antiangiogenic, tubulin-binding drug combretastatin A-4 exhibits a selective toxicity for pro
34 totoxic and antitubulin activity compared to combretastatin A-4 in neuroblastoma cells, showing a bet
37 icate that the selective cytotoxic effect of combretastatin A-4 is mediated by the induction of apopt
38 tected with either the colchicine site agent combretastatin A-4 or with an analog of the antimitotic
39 and the cancer antiangiogenesis drug sodium combretastatin A-4 phosphate (2b), syntheses of certain
42 nd is achievable with at least three agents, combretastatin A-4 phosphate, pigment epithelium-derived
46 expectedly obtained by Jacobsen oxidation of combretastatin A-4 silyl ether (1c --> 3a), and the pare
48 ion (IC50 = 22 microM, versus 1.2 microM for combretastatin A-4), while 4d was inactive (IC50 > 40 mi
49 structure of a known microtubule inhibitor, combretastatin A-4, Borowiak et al. develop a photoswitc
50 ture of the tubulin polymerization inhibitor combretastatin A-4, the possibility exists that the rati
53 In this study the effect of a CA-4 prodrug, combretastatin A-4-phosphate (CA-4-P), was tested in two
62 series of carbazole sulfonamides related to Combretastatin A4 (1) were synthesized and evaluated for
64 st potent compounds exceeded the activity of combretastatin A4 (CA-4), showing single digit nM IC50 v
66 CA4P was rapidly converted to the active combretastatin A4 (CA4), which was further metabolized t
67 phorylation of the parent compound (CA4P) to combretastatin A4 (CA4), with a short plasma half-life (
68 small molecule VTAs: the antitubulin drugs, combretastatin A4 phosphate (CA4P) and ZD6126, and the f
70 ute effects of the vascular disrupting agent combretastatin A4 phosphate (CA4P) on luciferase-express
71 the effects of the vascular targeting agent combretastatin A4 phosphate (CA4P) on tumor and normal t
72 Vascular-disrupting agents (VDAs) such as combretastatin A4 phosphate (CA4P) selectively disrupt b
74 cy of microtubule-disrupting agents, such as combretastatin A4 phosphate (CA4P), in inducing rapid re
76 ons of the selective vascular-targeting drug combretastatin A4 prodrug (CA4P) or anecortave acetate,
77 In contrast, the vascular disrupting agent combretastatin A4-phosphate, which caused a similar amou
79 eries of novel pyridine-bridged analogues of combretastatin-A4 (CA-4) were designed and synthesized.
80 tion on vascular and therapeutic response to combretastatin-A4 3-O-phosphate (CA-4-P), which was chos
81 xic doses of microtubule-destabilizing agent combretastatin-A4-phosphate (CA4P) inhibit leukemic cell
82 treatment with the vascular targeting agent, combretastatin A4P, or the antiangiogenic agent, contort
83 have developed a modular synthetic route to combretastatin analogs based on a pyrazole core through
85 w assesses the in vitro and in vivo data for combretastatin and the prodrug, and the preliminary data
87 of a new family of macrocyclic analogues of combretastatins B combining oxygenated substituents on t
89 D-2 and D-4 as well as a formal synthesis of combretastatin D-1 by a conceptually new route harnessin
90 ld be prepared as a side product en route to combretastatin D-2 by synchronous extrusion of SO2 and C
93 arried out to develop a predictive model for combretastatin-like analogues populating the colchicine-
94 COMPARE analysis led to the discovery of a combretastatin-like quinoline-5,8-dione structure that,
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。